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Little is known about specific naturally occurring mutations of hepatitis B virus (HBV) and underlying mechanisms of their association with
fulminant hepatitis. A HBV clone isolated from a patient with fulminant hepatitis was analyzed, and the features of the particular mutations observed
around furin cleavage site in core region (A2339G/G2345A)were assessed using an in vitro replicationmodel. The clone belonged to genotypeBwith
precore stop codon mutation (G1896A). Replication efficiency of 1.24-fold HBV genome in Huh-7 cells was increased in the presence of A2339G.
Further in vitro studies using furin inhibitor indicated that the effect of the mutation was probably associated with accumulation of the full-length core
protein without cleavage by furin-like protease, suggesting that a processing of the core protein might play an important role in regulation of viral
replication. In conclusion, the A2339G mutation was considered as one of the viral factors involved in high replication efficiency.
© 2007 Elsevier Inc. All rights reserved.Keywords: Hepatitis B virus; Core protein; Genotype; Furin; Fulminant hepatitis; ReplicationIntroduction
Hepatitis B virus (HBV) remains a major human pathogen.
Although new infections are preventable through vaccination, new
antiviral targets are being sought for the treatment of the estimated
350 million affected individuals worldwide (Lee, 1997). While
acute infection with HBV resolves in the great majority of patients,
in a proportion of patients HBV can induce fulminant hepatitis or
go on to become chronic hepatitis. What factors influence the
fulminant or chronic outcome of acute HBV infection are not fully
defined. Approximately 10% of adults and 90% of children
become persistent HBV carriers after HBV infection, and 1–2
million people die annually as the consequence of infection with
the virus, due to liver cirrhosis and hepatocellular carcinoma.☆ The nucleotide sequence of HBV-DNA isolates used in this study has been
deposited in the international DNA database under accession number AB302095.
⁎ Corresponding author. Fax: +81 52 842 0021.
E-mail address: mizokami@med.nagoya-cu.ac.jp (M. Mizokami).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.04.004HBV is the prototype strain of the family Hepadonaviridea.
The virus has an approximately 3.2 kb circular, double-stranded
DNA genome with four open reading frames: core (C),
polymerase (P), surface (S), and X. Eight genotypes have
been detected with a sequence divergence greater than 8% in the
entire HBV genome (Okamoto et al., 1988) and been designated
by capital alphabet letters from A (HBV/A) to H (HBV/H) in
the order of their discovery (Arauz-Ruiz et al., 2002; Norder et
al., 1994; Stuyver et al., 2000). The genotypes have distinct
geographical distributions and are associated with differing
severities of liver disease as well as response to antiviral
therapies (Chu and Lok, 2002; Kao, 2002; Miyakawa and
Mizokami, 2003).
The core region encodes two gene products, core protein and
HBe antigen (HBeAg), translated from two different transcripts
of 3.5 and 3.6 kb, respectively; the differences of the two
products were; however, only the amino acids at the N-
terminus. Most of the synthetic pathway of HBeAg is now
clearly established. In 2003, Messageot and colleagues reported
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154 and that a proprotein convertase, furin, was involved in the
maturation (Messageot et al., 2003).
Furin or furin-like protease is a transmembrane proprotein
convertase localized in the trans-Golgi network (TGN),
transported to the plasma membrane and then retrieved back
through the endocytic pathway (Molloy et al., 1999). The
consensus sequence of the furin cleavage site is RXK/RR, which
has strictly required arginine residues at both the head and tail of
the cleavage site (Nakayama, 1997). The furin cleavage site of
the HBeAg C-terminus was reported as 151RRGR154 (Fig. 1)
(Messageot et al., 2003). Therefore, their results strongly
indicate that the secretory HBeAg ends at Arg154.
Recently, a patient was referred to our hospital for
developing fulminant hepatitis B. Sequence analysis of the
causal HBV revealed naturally occurring A2339G and G2345A
mutations in the core region, and harboring the precore stop
codon G1896A mutation. The replication efficiency in vitro of
these clones was significantly higher than other clones with the
G1896A mutation, which had been constructed before (unpub-
lished data). The novel mutations may be responsible for the
higher replication efficiency since the region of the mutation
sites is adjacent to the furin cleavage site. To elucidate the
biological properties of naturally occurring mutations, although
the synthetic and secretory pathways of the core protein are not
completely understood, we investigated whether the A2339G
and/or G2345A mutations influence viral replication following
transient transfection into human hepatoma cell lines.
Results
Influence of A2339G on HBV replication
A serum sample was obtained from a patient with fulminant
hepatitis, in whom prothrombin time decreased less than 40% of
the controls with hepatic encephalopathy of grade II or more
within 8 weeks after the onset of the disease. The results of
sequence analysis revealed unique mutation, A2339G and
G2345A, in core gene. Then, we constructed plasmids with orFig. 1. C-terminus amino acid sequences and substitution mutants of the core pro
sequence and the C gene. Conventionally, position number 1 is assigned to the first a
terminus of the precore protein ends at Arg154. The amino acid of the putative furin cl
the upper line. Names of all of the substitution mutants referred to in this paper are o
indicated in bold and with an asterisk.without mutations and examined virological characteristics (Fig.
1). Huh-7 cells were transfected in 10-cm dish with 5 μg of each
plasmid and harvested 2 days posttransfection. Southern blot
analysis of core-associated HBV DNA in the cell lysate
demonstrated that transfection of both pBj_2339 and
pBj_2339/45 showed approximately 1.4-fold increase of core-
associated HBV DNA as compared to the pBj_wild construct
(Fig. 2A), while the transfection of pBj_2345 construct did not
reveal the different result from wild type. The difference between
these plasmids resides only in the mutations present in the core
gene, as shown in Fig. 1. The transfection efficiency was
monitored by reporter plasmids expressing secreted alkaline
phosphatase (SEAP). But the correction of the transfection
efficiency was not performed because each experiment in this
study showed almost equal value. For immunoblot analysis, a
particular monoclonal antibody was adopted. Because the anti-
core protein monoclonal antibodies (HB50) recognize SPRRR
repeats in the arginine-rich domain of core protein, only the full-
length core protein, which is not cleaved by furin-like protease,
can be detected by the HB50 antibody. Immunoblot analysis of
cell lysate revealed approximately 1.3-fold increase of the core
protein in pBj_2339 and pBj_2339/45 transfection (Fig. 2A) as
compared to pBj_wild and pBj_2345, indicating that theA2339G
mutation could be associated with the high expression of the core
protein. This was not due to larger amounts of sample of the
A2339G mutants, as revealed by reprobing of the same blot with
anti-α-tubulin antibodies (lower panel in Figs. 2A and B).
Transfection efficiency was monitored by cotransfection with a
gene encoding SEAP. These results were confirmed by at least
three replicates. Additionally, similar results were also obtained
when these clones were used for transfection ofHepG2 cells (data
not shown).
The A2339G mutation obstructed the function of a cellular
proprotein convertase
Precore proprotein undergoes enzymatic maturation by a
protease activated both in the post-endoplasmic reticulum
compartment and at the cell surface, which is a well knowntein. The ORF contains two in-frame initiation codons, delimiting the precore
mino acid of the core protein. As reported previously by Messageot et al., the C-
eavage site is underlined. The wild-type sequence of the core protein is shown on
n the left. In each case the corresponding sequence is shown, with the mutation
Fig. 3. Immunoblot analysis of core protein expression by the mutants ex-
pressing the core gene only. Huh-7 cells were transfected with both pcDNA/core
expression vector and reporter plasmid with SEAP, and harvested 2 days
posttransfection. Immunoblot analysis was performed to determine the ex-
pression levels of core protein and α-tubulin by HB50 (anti-core monoclonal
antibody) and anti-α-tubulin monoclonal antibody, respectively. (A) Samples
were collected from transfected cells cultured in the inhibitor-free medium.
(B) Cell lysates were prepared for analysis at a concentration of 20 μM dec-
RVKR-cmk.
Fig. 2. Replication of the A2339G and/or G2345A mutants with or without
20 μM furin specific inhibitor, decanoyl-RVKR-chloromethylketone (dec-
RVKR-cmk). Southern blot analysis of intracellular HBV replication. Isolated
core-associated HBV DNAs were separated on a 1.2% agarose gel. Immu-
noblot analysis of core protein expression from the various constructs was
performed by using HB50 monoclonal antibody. The blots were stripped of the
antibodies and reprobed with a mouse anti-α-tublin antibody. (A) Without the
specific inhibitor. (B) With 20 μM specific inhibitor. These results were
confirmed by at least three replicates. ss: single strand DNA, ds: double strand
DNA.
287M. Sugiyama et al. / Virology 365 (2007) 285–291characteristic of furin. As the ORF of the core protein C-terminus
is the same as the precore proprotein, core protein might have a
similar processing step by furin. To determine whether furin-like
protease is the protease involved in core maturation, a specific
inhibitor, decanoyl-RVKR-chloromethylketone (dec-RVKR-
cmk), was used in the next experiment. The inhibitor, at a
concentration of 20 μM, was added into the medium and was
maintained through to the cell lysis stage. As shown in Fig. 2B,
under these conditions, the replication levels of pBj_wild and
pBj_2345 became quite equal to pBj_2339 and pBj_2339/45.
The expression levels of the core protein were not different
between each plasmid (Fig. 2B). Thus, inhibition of the
proteolytic activity of furin could induce the increase of both
HBV replication and core protein expression, indicating that this
protease is involved in the processing pathway of the core
protein.Influence on the replication capacities by the amount of
core protein
As the replication capacity correlated well with the expres-
sion levels of core protein (Fig. 2), it would be insufficient to
analyze the influence of the core protein on replication efficiency
using the above replication model. To determine whether the
core protein harboring the A2339G mutation avoids processing
by furin-like protease, we generated expression plasmids
encoding the core gene only. These plasmids drive the synthesis
of wild type, A2339G, G2345A, or A2339G/G2345A core
protein from the cytomegalovirus promoter, which were named
pcDNA/core_wild, core_2339, core_2345, and core_2339/45,
respectively. Transient expression of the core protein was
achieved by transfection of Huh-7 cells with these plasmids. The
transfection efficiency was monitored by SEAP. Immunoblot
analysis showed higher expression levels of the uncleaved core
protein for core_2339 and core_2339/45 than that for core_wild
and core_2345 in conditions without furin inhibitor (Fig. 3A). In
contrast, in the presence of the furin inhibitor, the amounts of
full-length core protein were equal between each of the plasmid
(Fig. 3B). These results were consistent with those from
experiments using the 1.24-fold HBV genome as shown in
Fig. 2; the A2339G mutation may enhance full-length core
protein expression as well as viral replication due to the
inhibition of core protein processing by furin-like protease.
No influence of furin against core protein processing
It is well-known that furin inhibitor has the ability to inhibit
some proteases. To specifically silence furin, we designed
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et al., 2005). The ability of furin siRNA to suppress the ex-
pression of furin protein was validated by transfecting siRNA in
Huh-7 cells. Immunoblot analysis revealed that the designed
sequence specifically abolished furin expression in Huh-7 cells,
whereas expression of α-tubulin was not affected 2 days
posttransfection (Fig. 4A). As the effect of siRNA was con-Fig. 4. Influence of viral replication and core protein expression by using siRNA
specific for furin. (A) Huh-7 cells were transfected with either siRNA specific
for furin or control siRNA (1 μg), and harvested 2 days posttransfection.
Immunoblot analysis was performed to confirm the knock-down of furin.
(B) Both siRNA (1 μg) and HBV DNA (5 μg) were transfected into cells under
the knock-down of furin. The replication efficiency was analyzed by southern
blot analysis and the expression levels of core protein, furin, and α-tubulin were
detected by immunoblot analysis using HB50 (anti-core monoclonal antibody),
anti-furin polyclonal antibody, and anti-α-tubulin monoclonal antibody,
respectively. (C) The expression vector harboring core gene, either pcDNA/
core_wild or pcDNA/core_2339, was transfected into Huh-7 cells 2 days after
siRNA specific for furin was transfected. The levels of core expression were
examined by immunoblot analysis under the knock-down of furin.firmed, in addition, both HBV plasmid and siRNA were
transfected 2 days after the initial transfection of siRNA. To
elucidate the effect of the A2339G mutation on viral replication
under down-regulation of furin, we performed southern blot
analysis using purified HBV DNA from intracellular core
particles additional 2 days after the second transfection. The
similar trend was observed between siRNA-Control and
siRNA-Furin treatment; the viral replication as well as core
expression were enhanced by the A2339G mutant regardless of
the furin expression levels (Fig. 4B). To confirm these results,
we investigated the amount of the full-length core protein under
conditions down-regulating furin expression by using a
transient transfection of core expression vector derived CMV
promoter. Immunoblot analysis using anti-core monoclonal
antibody (HB50) showed that core expression was enhanced by
the A2339G mutant regardless of the furin expression levels
(Fig. 4C). Therefore, the influence of furin was not detected in
these experiments.
Replication of the A2339G mutant rescued by full-length core
protein in trans
To elucidate whether A2339G mutant can influence the viral
replication of wild-type clone in trans, the construct with
pBj_wild or pBj_wild core(−) vector was cotransfected with
either pcDNA/core_wild or pcDNA/core_2339, using a ratio
2:1. The pBj_wild core(−) construct was derived from the
core_wild construct by a nonsense mutation in the core gene. As
illustrated in Fig. 5, the low intra-cellular DNA level of wild-
type clone was rescued by cotransfection with the core_2339
vector but not with the core_wild vector, resulting in similar
replication levels of pBj_2339 and pBj_2339/45 as shown in
Fig. 2. Therefore the virtue of the A2339G mutant indeed lies at
the core protein levels rather than at the polymerase or the
pregenomic RNA levels.
Prevalence of the A2339G mutation in GenBank
To examine the influence of the A2339G mutation on the
outcomes of patients, all available published complete or partial
core genome sequences of HBV were recruited from interna-
tional data base (1507 entries excluding 74 from non-human
primates, June 2006). Twenty-seven independent sequences
with the A2339G mutation were found in the database as well as
one unpublished sequence from another patient with fulminant
hepatitis in our hospital. The prevalence of A2339G mutation in
genotype B strains was significantly higher than that in the other
genotypes (6.3% vs. 1.1%, pb0.001) (Table 1). Interestingly,
acute exacerbation or fulminant hepatitis was found to be
associated with genotype B only; 8/14 (57.1%). Six of the 8
strains had precore stop mutation (G1896A) as well as A2339G
mutation.
Discussion
In the present study, the A2339G mutation was shown to
enhance the replication of HBV in vitro.We initially investigated
Table 1
Prevalence of A2339G mutation among HBV genotypes strains recruited from
international data base
Genotype
(N)
A2339G
(%)
Outcomes
Fulminant
hepatitis
(with G1896A)
Acute
exacerbation
(with G1896A)
Chronic
hepatitis
(with G1896A)
A (218) 4 (1.8%) 0 0 4 (0)
B (222) 14 (6.3%) ⁎ 4 (4) 4 (2) 6 (4)
C (453) 5 (1.1%) 0 0 5 (1)
D (384) 4 (1.0%) 0 0 4 (4)
E (164) 0 (0%) 0 0 7
F (43) 0 (0%) 0 0 0
G (13) 0 (0%) 0 0 0
H (10) 1 (10%) 0 0 1 (0)
Total (1508) 28 (1.9%) 4 (4) 4 (2) 20 (9)
⁎ pb0.001: Genotype B with A2339G vs. the other genotypes with it by Chi
square test (Yates' correction).
Fig. 5. Rescue of the replication of wild-type clone, either pBj_wild or pBj_wild
core(−), by the core protein provided in trans. (A) Rescue of pBj_wild clone.
(B) Rescue of pBj_wild core(−) clone. Each replication construct (5 μg) was
cotransfected with 2.5 μg of pcDNA/core_wild or pcDNA/core_2339.
Intracellular HBV DNA was analyzed by Southern blotting as described
above. The levels of core expression in cell lysate were determined by
immunoblot analysis using HB50 monoclonal antibody.
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mutation against the replication of HBV, and found that
acceleration of HBV replication is compatible with an increase
in the level of the full-length core protein under conditions using
furin inhibitor. Immunoblot analysis using core gene expression
vector or the 1.24-fold HBV genome showed that the A2339G
mutationmay be associated with inhibition of the cleavage of the
core protein by a furin-like protease, resulting in the high
expression of the complete core protein. The A2339G mutation
within the consensus recognition sites of furin-like protease
might interfere with the recognition, binding, and/or processing
by protease.
Cotransfection of the 1.24-fold the wild-type full-genome
with the core protein expression vector harboring the A2339G
mutation that provides core protein in trans enhanced the
replication of HBV as compared with the wild type. Core
protein with the A2339G mutation could work as a trans-acting
regulator of HBV replication. This may reveal the reason for the
aggravation of outcomes when the A2339G mutant has been
shown for quasispecies or coinfections.
Furin or furin-like protease, a subtilisin-like mammalian
endoprotease, is a proprotein convertase that processes latent
precursor proteins into their biologically active forms. Furin is a
calcium-dependent serine endoprotease that can efficiently
cleave precursor proteins at paired basic amino acid processing
sites (Julius et al., 1984). It is thought to be responsible for the
processing of many protein precursors of viral as well as cellular
origin, including gp160 and gp140 of human immunodeficiency
virus type 1 (Hallenberger et al., 1992; Morikawa et al., 1993),
which share the same consensus processing sites. A study to
confirm and extend the concept that gp160 is processed by furin
has been performed by using a cell line, LoVo, which is
demonstrated to be furin-defective (Ohnishi et al., 1994). Un-
expectedly, LoVo cells were shown to process gp160 as effi-ciently as normal cell lines do, being capable of producing fully
infectious virions (although Newcastle disease virus fusion
glycoprotein was not processed in the same cell lines). Thus the
processing of core protein was not completely influenced by
furin alone, although furin inhibitor worked in the present study.
Furin inhibitor could also interfere with the activity of other
proteases. These findings raise a further need to search for and
identify the proteases involved in core protein processing.
HBV genotypes have distinct geographical distributions and
are associated with differing severities of liver disease as well as
response to antiviral therapies (Chu and Lok, 2002; Kao, 2002;
Miyakawa and Mizokami, 2003). In previous studies, the
majority of patients with fulminant hepatitis and fatal acute
exacerbation of chronic hepatitis were found to have a G1896A
precore stop codon mutation (Liang et al., 1991; Omata et al.,
1991), core promoter (A1762T/G1764A) mutation, HBeAg-
negative, or HBV/Bj as independent risk factors (Imamura et
al., 2003; Ozasa et al., 2006). Various mutations at nt 1753 for
enhanced HBV replication, as well as those adjacent at nt 1754
occurred frequently in patients with fulminant hepatitis
(Imamura et al., 2003). In our study, acute exacerbation or
fulminant hepatitis was relatively prevalent when outcomes of
patients with the entire HBV genome or partial core sequences
harboring the A2339G mutation in GenBank were analyzed.
Fourteen of the sample sequences were classified into HBV/B.
To our surprise, the majority (57.1%) of HBV/B sequences
harboring A2339G have been reported as acute exacerbation or
fulminant hepatitis while no entries with it were found in the
other genotypes. Details included 4 patients with fulminant
hepatitis and the remaining 4 patients with acute exacerbation of
chronic hepatitis. Because of high replication levels of HBV
with the A2339G mutation, patients with the mutation in the
HBV genome would correlate with acute exacerbation during
long-lasting HBV infection as well as in the fulminant form of
acute infection.
It was reported that the A2339G mutation corresponding to
core protein codon 147 was located in the epitopes of the
cytotoxic T lymphocyte (CTL) in the core region (Missale et al.,
1993). The CTL response to this epitope is dually restricted by
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Aw68 alleles. This may cause the differences in outcomes even
if the mutation exists in the core region. As well, the A2339G
mutation at core protein codon 147 was frequently found in 9
(29%) of 31 chronic HBV-infected children, although it has not
reached a statistically significant difference between pre-
HBeAg seroconversion and post-seroconversion (Ni et al.,
2003). Children with the codon 147 mutation had higher peak
alanine aminotransferase (ALT) levels than those without the
mutant when peak ALT levels before HBeAg seroconversion
were compared between these two groups.
In conclusion, by elucidating the effect of the A2339G
mutation we suggested that the viral replication level might be
associated with a processing of its core protein by furin-like
protease. Although the mutation A2339G might be considered
as one of the viral factors involved in development of fulminant
hepatitis, further studies are required to investigate details to this
association and its clinical implication.
Materials and methods
Patients
A serum sample was obtained from a patient with fulminant
hepatitis in Saitama Medical University Hospital, in whom
prothrombin time decreased less than 40% of the controls with
hepatic encephalopathy of grade II or more within 8 weeks after
the onset of the disease. HBV clones from the patients belong to
genotype B and had precore stop codon mutation (G1896A),
but not the A1762T/G1764A double mutation in the core
promoter. The study design conformed to the 1975 Declaration
of Helsinki, and was approved by the Ethic Committees of
Institutions. An informed consent was obtained from a patient.
Plasmid constructs of HBV DNA and sequencing
A consensus clone was used for plasmid construction as
reported previously (Ozasa et al., 2006). The clone was named
pBj_39, which corresponds to pBj_2339/45 with A2339G and
G2345A mutations in the core region. Fig. 1 illustrates the
mutants assessed in this study. Each mutation was introduced
into the construct by overlap extension PCR. The PCR products
were digested with HindIII and EcoO65I for cloning back into
the pBj_2339/45 construct. In addition, we generated expres-
sion plasmids encoding the core gene only. The core gene was
inserted into pcDNA3.1/Hyg (Invitrogen Corp., Carlsbad, CA).
These plasmids were capable of driving the synthesis of wild
type, A2339G, G2345A, or A2339G/G2345A core protein from
the cytomegalovirus promoter.
Cell culture and transfection
Huh-7 cells were maintained in Dulbecco's modified Eagle's
medium containing 10% fetal bovine serum. For the standard
replication assay, 10-cm-diamater dishes were seeded with
1×106 cells per dish. After 16 h of incubation, Huh-7 cells were
transfected with 5 μg of DNA construct using the Fugene 6transfection reagent (Roche Diagnostics, Indianapolis, IN) and
harvested 48 h later. Transfection efficiency was measured by
cotransfection with 0.5 μg of a reporter plasmid expressing
secreted alkaline phosphatase (SEAP) and estimating SEAP
enzymatic activity in the culture supernatant. Three replicate
experiments were conducted for each clone. For RNAi-
mediated knockdown of furin, we referred to the previous
report for the sequence to design target-specific siRNA duplex
against furin (Jansen et al., 2005). We obtained a 21-nt sense
and antisense strand with symmetric 2-nt 3′ overhangs of
identical sequences (sense siRNA: 5′-GAC CAT TCG ACC
AAA CAG TdTdT-3′). Scramble oligo-ribonucleotide duplex
that was not homologue to any mammalian genes was utilized
as control (sense siRNA: 5′-TTC TCC GAA CGT GTC ACG
TdTdT-3′) (Little et al., 2007). Transient transfections of
siRNAs in Huh-7 cells were carried out using X-tremeGene
siRNATransfection Reagent (Roche Diagnostics, Indianapolis,
IN).
Isolation of core-associated HBV DNA from transfected cells
and Southern Blot hybridizations
HBV DNA was purified from intracellular core particles by
the method described previously (Fujiwara et al., 2005).
Southern blot hybridizations were performed with a full-length
probe by the method described previously (Ozasa et al., 2006).
Immunoblot analysis of core protein
Huh-7 cells grown in each well of the dishes were scraped at
day 2 after transfection, and the cell pellet was lysed with
CellLytic-M buffer (SIGMA, St. Louis, MO). Proteins from
10 μl of lysate were separated on a 0.1% SDS–15% poly-
acrylamide gel and transferred to Hybond ECL nitrocellulose
membrane (Amersham Biosciences Corp, Piscataway, NJ). A
mouse monoclonal anti-core antibody (HB50, kindly provided
by Advanced Life Science Institute Inc.) that specifically
recognizes SPRRR repeats in the arginine-rich domain of the
core protein was used as the primary antibodies. To control for
transfection efficiency, the blots were stripped with Restore
Immunoblot stripping buffer (Pierce, Rockford, IL). The blots
were incubated with a mouse monoclonal α-tubulin antibody
(Zymed Laboratories, South San Francisco, CA). The proteins
were detected by anti-mouse antibody HRP-linked IgG
(Amersham Biosciences Corp, Piscataway, NJ).
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